ANA DEVELOPMENT IS ASSOCIATED WITH POOR RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Ishikawa, Y. [1 ]
Hashimoto, M. [2 ]
Ito, H. [2 ,3 ]
Tanaka, M. [2 ]
Yukawa, N. [4 ]
Fujii, T. [4 ]
Mimori, T. [5 ]
Terao, C. [6 ]
机构：
[1] Harvard Med Sch, Immunobiol Sect, Joslin Diabet Ctr, Boston, MA USA
[2] Kyoto Univ, Grad Sch Med, Dept Adv Med Rheumat Dis, Kyoto, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Orthoped Surg, Kyoto, Japan
[4] Wakayama Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Wakayama, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto, Japan
[6] RIKEN, Ctr Invest Med Sci, Yokohama, Kanagawa, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1232
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0114
引用
收藏
页码：107 / 108
页数：2
相关论文
共 50 条
  • [1] Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Ishikawa, Yuki
    Hashimoto, Motomu
    Ito, Hiromu
    Tanaka, Masao
    Yukawa, Naoichiro
    Fujii, Takao
    Yamamoto, Wataru
    Mimori, Tsuneyo
    Terao, Chikashi
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (02) : 204 - 210
  • [2] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [3] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    [J]. SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [4] Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
    Su, Yu-Jih
    Chen, Hui-Ming
    Chan, Tien-Ming
    Cheng, Tien-Tsai
    Yu, Shan-Fu
    Chen, Jia-Feng
    Lin, Chun-Yu
    Hsu, Chung-Yuan
    [J]. RMD OPEN, 2023, 9 (03):
  • [5] Development of a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs
    Song, Fang
    Nakatani, Hisae
    Sugiyama, Eiji
    Hirata, Shintaro
    [J]. MODERN RHEUMATOLOGY, 2024, 34 (03) : 479 - 487
  • [6] THE IMPACT OF BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON THE COURSE OF RHEUMATOID ARTHRITIS-ASSOCIATED LUNG DISEASE
    Avsar, A. Koken
    Can, G.
    Birlik, M.
    Sari, I.
    Onen, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 624 - 625
  • [7] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    [J]. CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [8] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [9] Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis
    Haibel, H.
    Specker, C.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (04) : S159 - S163
  • [10] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    [J]. Clinical Rheumatology, 2020, 39 : 207 - 216
12345